Ann: CEO's address to AGM , page-8

Very impressive transcript from LG.

Only real downsides & they are all out of the control of the company is everything is running behind schedule, but in condolence it is the nature of the industry - everything takes that bit longer.

I do really like the opening paragraph -

"The logic that has driven the company since the beginning is the same logic that drives us now. Twenty years ago, Professor Peter Gluckman (now Professor Sir Peter Gluckman), Neuren’s scientific founder, published a paper highlighting the role of IGF-1 in neurology1. NNZ-2566 is a direct, linear descendent of that work and the succeeding two decades of international research on IGF-1 and its derivatives. Across our neurology portfolio, the drugs that we’re developing are improved versions of naturally occurring molecules -molecules produced by the brain in response to acute and chronic injury. We don’t start with a molecular target then screen large numbers of compounds to find which ones interact with the target. We start with molecules that result from millions of years of evolution, that we know work, then modify them only to the extent necessary to make them suitable drug candidates."